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Chemotherapy faces the problem of chemo-resistance in
large part of tumors, leading to the appearance of
metastasis difficult to eliminate. Over the past decade an
improved understanding of the effect of immunogenic
chemotherapy on tumor-host interactions has led to the
concept of immunogenic cell death (ICD), a type of cell
death capable to convert a tumor into an in situ vaccine
through the generation of danger signals, dendritic cells
activation an finally breaking tolerance, which leads to
the destruction of residual tumor cells. Polyphenols are
natural compounds from plants, traditionally used for
cancer treatment, that exhibit multiple biological activ-
ities including anti-oxidation, anti-angiogenesis and pro-
apoptosis, which together may exert potent anti-tumor
activity. However, little is known about the mechanism
of action of polyphenols. We previously obtained a nor-
malized polyphenol rich fraction from Ceasalpina spi-
nosa (P2Et) that exerted cytotoxic activity on several
tumor cell lines. Moreover, P2Et showed anti-tumor
activity in the 4T1 transplantable model through ICD
induction. Vaccination with P2Et-pretreated 4T1 cells
yielded long lasting ex vivo IL-2, TNF-a, IL-4, IL-5, and
IFN-g secreting multifunctional T cells after specific 4T1
cell stimulation. In this work we investigate the activa-
tion of the immune system after in vivo P2Et treatment
of B16 tumor bearing mice. Analysis of spleen, lymph
nodes and tumors shows increase numbers of CD44
high, CD4 and CD8 T cells, as well as NK cells in P2Et
treated mice compared to non-treated ones. In addition,
in vitro, phagocytosis of P2Et treated tumor cells induce
activation of DC, and in vivo P2Et induces recruitment
and activation of cross-presenting DCs (CD11c+, CD11b+,
Ly6C+ or CD11c+ CD8a+) in spleen and tumors, which
could lead to the effective activation of CD8 T cells
favoring a better tumor control. In fact, vaccinated mice
treated with P2Et cells are able to effectively control the
growth of transplanted tumor. Accordingly, we observed
that P2Et anti-tumor activity is highly dependent on an
intact immune system, as P2Et anti-tumor activity is lost
in RAG gc KO immunodeficient mice. In summary, P2Et
exert its anti-tumor activity through the activation of the
endogenous immune system, playing an important role
not only in the destruction of the primary tumor but also
in controlling metastasis.
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